Chronic Liver Failure and Hepatic Cirrhosis

Chapter

Keywords

Hepatitis Chronic liver disease Hepatic fibrosis Liver failure Cirrhosis Portal hypertension 

Abbreviations

AASLD

American Association for the Study of Liver Diseases

AH

Alcoholic hepatitis

ATP

Adenosine triphosphate

CDC

Center for disease control

CTP

Child-Turcotte-Pugh

ECM

Extracellular matrix

HBV

Hepatitis B virus

HCC

Hepatocellular carcinoma

HCV

Hepatitis C virus

HPS

Hepatopulmonary syndrome

HRS

Hepatorenal syndrome

HSC

Hepatic stellate cell

HVPG

Hepatic venous pressure gradient

IL

Interleukin

MDF

Maddrey discriminant function

MELD

Model for end-stage liver disease

NAFLD

Nonalcoholic fatty liver disease

NASH

Nonalcoholic steatohepatitis

POPH

Portopulmonary hypertension

PSE

Portosystemic encephalopathy

PVT

Portal venous thrombosis

SAAG

Serum-ascites albumin gradient

SBP

Spontaneous bacterial peritonitis

TGF

Transforming growth factor

TIPS

Transjugular intrahepatic portosystemic shunt

TLRs

Toll-like receptors

TNF

Tumor necrosis factor

USPSTF

United States preventative services task force

References

  1. 1.
    Heron M. Deaths: Leading Causes for 2014. Natl Vital Stat Rep. 2016;65:1–96.Google Scholar
  2. 2.
    Scaglione S, et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol. 2015;49(8):690–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Graudal N, et al. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. J Intern Med. 1991;230(2):165–71.CrossRefPubMedGoogle Scholar
  4. 4.
    Giarelli L, et al. Occurrence of liver cirrhosis among autopsies in Trieste. IARC Sci Publ. 1991;112:37–43.Google Scholar
  5. 5.
    Mokdad AH, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195–200.CrossRefPubMedGoogle Scholar
  6. 6.
    Hsu CC, et al. Poverty increases type 2 diabetes incidence and inequality of care despite universal health coverage. Diabetes Care. 2012;35(11):2286–92.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Denniston MM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293–300.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mellinger JL, et al. Variation among United States hospitals in inpatient mortality for cirrhosis. Clin Gastroenterol Hepatol. 2015;13(3):577–84. quiz e30CrossRefPubMedGoogle Scholar
  9. 9.
    Younossi ZM, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–530.e1. quiz e60CrossRefPubMedGoogle Scholar
  10. 10.
    Wong RJ, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Chalasani N, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.CrossRefPubMedGoogle Scholar
  12. 12.
    Williams CD, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31.CrossRefPubMedGoogle Scholar
  13. 13.
    Bellentani S, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155–61.CrossRefPubMedGoogle Scholar
  14. 14.
    Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5).  https://doi.org/10.3390/ijms17050774.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Goh GB, McCullough AJ. Natural history of nonalcoholic fatty liver disease. Dig Dis Sci. 2016;61(5):1226–33.CrossRefPubMedGoogle Scholar
  16. 16.
    O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology. 2010;51(1):307–28.CrossRefPubMedGoogle Scholar
  17. 17.
    Teli MR, et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet. 1995;346(8981):987–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Leevy CM. Fatty liver: a study of 270 patients with biopsy proven fatty liver and review of the literature. Medicine. 1962;41:249–76.CrossRefPubMedGoogle Scholar
  19. 19.
    Sorensen TI, et al. Prospective evaluation of alcohol abuse and alcoholic liver injury in men as predictors of development of cirrhosis. Lancet. 1984;2(8397):241–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.CrossRefPubMedGoogle Scholar
  21. 21.
    Blum HE. History and global burden of viral hepatitis. Dig Dis. 2016;34(4):293–302.CrossRefPubMedGoogle Scholar
  22. 22.
    Chan SL, et al. Infection and cancer: the case of hepatitis B. J Clin Oncol. 2016;34(1):83–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Lavanchy D, Mark K. Global epidemiology of hepatitis B virus infection. In: Liaw Y-F, Zoulim F, editors. Hepatitis B virus in human diseases. Cham: Springer International Publishing; 2016.Google Scholar
  24. 24.
    Ott JJ, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Wasley A, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202(2):192–201.CrossRefPubMedGoogle Scholar
  26. 26.
    McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98(1):39–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995;20(4):992–1000.CrossRefPubMedGoogle Scholar
  28. 28.
    Benlloch S, Berenguer M. Chronic viral hepatitis. Friedman SL, Keeffe EB, Dienstag JL, editors. Philadelphia: Elselvier Saunders; 2012.CrossRefGoogle Scholar
  29. 29.
    Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–52.CrossRefPubMedGoogle Scholar
  30. 30.
    Yang HI, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.CrossRefPubMedGoogle Scholar
  31. 31.
    Chen CJ, Yang HI, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72–84.CrossRefPubMedGoogle Scholar
  32. 32.
    Chen JD, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138(5):1747–54.CrossRefPubMedGoogle Scholar
  33. 33.
    El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–1273.e1.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Terrault NA, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.CrossRefPubMedGoogle Scholar
  35. 35.
    Ditah I, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014;60(4):691–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol. 2007;13(17):2436–41.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 Suppl 1):S35–46.PubMedGoogle Scholar
  38. 38.
    Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1–39.Google Scholar
  39. 39.
    Moyer VA. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5):349–57.CrossRefPubMedGoogle Scholar
  40. 40.
    Surveillance for Viral Hepatitis – United States, 2014. http://www.cdc.gov/hepatitis/statistics/2014surveillance/index.htm. Accessed 18 Aug 2016
  41. 41.
    Malhi H, Gores GJ. Mechanisms of liver injury. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff’s diseases of the liver. 11th ed. Chichester: John Wiley and Sons; 2012. p. 216–31.Google Scholar
  42. 42.
    Lemasters JJ. V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am J Phys. 1999;276(1 Pt 1):G1–6.Google Scholar
  43. 43.
    Lemasters JJ. Dying a thousand deaths: redundant pathways from different organelles to apoptosis and necrosis. Gastroenterology. 2005;129(1):351–60.CrossRefPubMedGoogle Scholar
  44. 44.
    Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology. 2006;43(2 Suppl 1):S31–44.CrossRefPubMedGoogle Scholar
  45. 45.
    Faouzi S, et al. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway. J Biol Chem. 2001;276(52):49077–82.CrossRefPubMedGoogle Scholar
  46. 46.
    Jaeschke H, Lemasters JJ. Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology. 2003;125(4):1246–57.CrossRefPubMedGoogle Scholar
  47. 47.
    Ogasawara J, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364(6440):806–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Matsumura H, et al. Necrotic death pathway in Fas receptor signaling. J Cell Biol. 2000;151(6):1247–56.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Trautwein C, et al. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62(1 Suppl):S15–24.CrossRefPubMedGoogle Scholar
  50. 50.
    Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209–18.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830–41.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Iwaisako K, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci U S A. 2014;111(32):E3297–305.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Lemoinne S, et al. Origins and functions of liver myofibroblasts. Biochim Biophys Acta. 2013;1832(7):|948–54.CrossRefPubMedGoogle Scholar
  54. 54.
    Mederacke I, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655–69.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Jarnagin WR, et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol. 1994;127(6 Pt 2):2037–48.CrossRefPubMedGoogle Scholar
  57. 57.
    Friedman SL. Hepatic fibrosis: emerging therapies. Dig Dis. 2015;33(4):504–7.CrossRefPubMedGoogle Scholar
  58. 58.
    Bosch J, et al. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol. 2010;53(3):558–67.CrossRefPubMedGoogle Scholar
  59. 59.
    Kawada N, et al. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem. 1993;213(2):815–23.CrossRefPubMedGoogle Scholar
  60. 60.
    Kaneda K, et al. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology. 1998;27(3):735–47.CrossRefPubMedGoogle Scholar
  61. 61.
    Zhang JX, Pegoli W Jr, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Phys. 1994;266(4 Pt 1):G624–32.Google Scholar
  62. 62.
    Gupta TK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998;28(4):926–31.CrossRefPubMedGoogle Scholar
  63. 63.
    Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749–61.CrossRefPubMedGoogle Scholar
  64. 64.
    Giannini EG, Savarino V. Thrombocytopenia in liver disease. Curr Opin Hematol. 2008;15(5):473–80.CrossRefPubMedGoogle Scholar
  65. 65.
    Garcia-Tsao G, et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922–38.CrossRefPubMedGoogle Scholar
  66. 66.
    Garcia-Tsao G, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5(3):419–24.CrossRefPubMedGoogle Scholar
  67. 67.
    Abraldes JG, et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37(4):902–8.CrossRefPubMedGoogle Scholar
  68. 68.
    Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651–3.CrossRefPubMedGoogle Scholar
  69. 69.
    Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease. 9th ed. Philadelphia: Saunder Elsevier; 2010.Google Scholar
  70. 70.
    Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087–107.CrossRefPubMedGoogle Scholar
  71. 71.
    Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med. 2016;375(8):767–77.CrossRefPubMedGoogle Scholar
  72. 72.
    Planas R, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4(11):1385–94.CrossRefPubMedGoogle Scholar
  73. 73.
    D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.CrossRefPubMedGoogle Scholar
  74. 74.
    Runyon BA. Care of patients with ascites. N Engl J Med. 1994;330(5):337–42.CrossRefPubMedGoogle Scholar
  75. 75.
    Gines P, et al. Management of cirrhosis and ascites. N Engl J Med. 2004;350(16):1646–54.CrossRefPubMedGoogle Scholar
  76. 76.
    Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis. 1998;27(4):669–74. quiz 675–6CrossRefPubMedGoogle Scholar
  77. 77.
    Hung TH, Tsai CC, Hsieh YH. The long-term mortality of spontaneous bacterial peritonitis in cirrhotic patients: a 3-year nationwide cohort study. Turk J Gastroenterol. 2015;26(2):159–62.CrossRefPubMedGoogle Scholar
  78. 78.
    Follo A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20(6):1495–501.CrossRefPubMedGoogle Scholar
  79. 79.
    Tito L, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology. 1988;8(1):27–31.CrossRefPubMedGoogle Scholar
  80. 80.
    Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis. 1997;17(3):227–32.CrossRefPubMedGoogle Scholar
  81. 81.
    Xiol X, et al. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology. 1996;23(4):719–23.CrossRefPubMedGoogle Scholar
  82. 82.
    D’Amico G, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131(5):1611–24.CrossRefPubMedGoogle Scholar
  83. 83.
    Bosch J, Garcia-Pagan JC. Prevention of variceal rebleeding. Lancet. 2003;361(9361):952–4.CrossRefPubMedGoogle Scholar
  84. 84.
    Vilstrup H, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35.CrossRefPubMedGoogle Scholar
  85. 85.
    Saunders JB, et al. A 20-year prospective study of cirrhosis. Br Med J. 1981;282(6260):263–6.CrossRefGoogle Scholar
  86. 86.
    Romero-Gomez M, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96(9):2718–23.CrossRefPubMedGoogle Scholar
  87. 87.
    Jepsen P, et al. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675–82.CrossRefPubMedGoogle Scholar
  88. 88.
    Coltorti M, et al. Liver cirrhosis in Italy. A multicentre study on presenting modalities and the impact on health care resources. National Project on Liver Cirrhosis Group. Ital J Gastroenterol. 1991;23(1):42–8.PubMedGoogle Scholar
  89. 89.
    Bustamante J, et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol. 1999;30(5):890–5.CrossRefPubMedGoogle Scholar
  90. 90.
    Lockwood AH. Blood ammonia levels and hepatic encephalopathy. Metab Brain Dis. 2004;19(3–4):345–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Bass NM, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.CrossRefPubMedGoogle Scholar
  92. 92.
    Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome—a liver-induced lung vascular disorder. N Engl J Med. 2008;358(22):2378–87.CrossRefPubMedGoogle Scholar
  93. 93.
    Zhang XJ, et al. Intrapulmonary vascular dilatation and nitric oxide in hypoxemic rats with chronic bile duct ligation. J Hepatol. 2003;39(5):724–30.CrossRefPubMedGoogle Scholar
  94. 94.
    Rodriguez-Roisin R, et al. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J. 2004;24(5):861–80.CrossRefPubMedGoogle Scholar
  95. 95.
    Corley DA, et al. Lack of efficacy of TIPS for hepatopulmonary syndrome. Gastroenterology. 1997;113(2):728–30.CrossRefPubMedGoogle Scholar
  96. 96.
    Allgaier HP, et al. Hepato-pulmonary syndrome: successful treatment by transjugular intrahepatic portosystemic stent-shunt (TIPS). J Hepatol. 1995;23(1):102.CrossRefPubMedGoogle Scholar
  97. 97.
    Lasch HM, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to liver transplantation in a patient with severe hepatopulmonary syndrome. Liver Transpl. 2001;7(2):147–9.CrossRefPubMedGoogle Scholar
  98. 98.
    Riegler JL, et al. Transjugular intrahepatic portosystemic shunt improves oxygenation in hepatopulmonary syndrome. Gastroenterology. 1995;109(3):978–83.CrossRefPubMedGoogle Scholar
  99. 99.
    Selim KM, et al. Transjugular intrahepatic portosystemic shunt: a successful treatment for hepatopulmonary syndrome. Am J Gastroenterol. 1998;93(3):455–8.CrossRefPubMedGoogle Scholar
  100. 100.
    Siramolpiwat S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol. 2014;20(45):16996–7010.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Krowka MJ. Hepatopulmonary syndrome: recent literature (1997 to 1999) and implications for liver transplantation. Liver Transpl. 2000;6(4 Suppl 1):S31–5.CrossRefPubMedGoogle Scholar
  102. 102.
    Pascasio JM, et al. Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation. Am J Transplant. 2014;14(6):1391–9.CrossRefPubMedGoogle Scholar
  103. 103.
    Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet. 2004;363(9419):1461–8.CrossRefPubMedGoogle Scholar
  104. 104.
    Surani SR, et al. Pulmonary complications of hepatic diseases. World J Gastroenterol. 2016;22(26):6008–15.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Kochar R, Nevah Rubin MI, Fallon MB. Pulmonary complications of cirrhosis. Curr Gastroenterol Rep. 2011;13(1):34–9.CrossRefPubMedGoogle Scholar
  106. 106.
    Budhiraja R, Hassoun PM. Portopulmonary hypertension: a tale of two circulations. Chest. 2003;123(2):562–76.CrossRefPubMedGoogle Scholar
  107. 107.
    Halank M, et al. Portopulmonary hypertension. J Gastroenterol. 2006;41(9):837–47.CrossRefPubMedGoogle Scholar
  108. 108.
    Swanson KL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8(11):2445–53.CrossRefPubMedGoogle Scholar
  109. 109.
    Salerno F, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut. 2007;56(9):1310–8.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Fede G, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56(4):810–8.CrossRefPubMedGoogle Scholar
  111. 111.
    Angeli P, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690–7.CrossRefPubMedGoogle Scholar
  112. 112.
    Esrailian E, et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742–8.CrossRefPubMedGoogle Scholar
  113. 113.
    Alessandria C, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47(4):499–505.CrossRefPubMedGoogle Scholar
  114. 114.
    Ghosh S, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013;33(8):1187–93.CrossRefPubMedGoogle Scholar
  115. 115.
    Nassar Junior AP, et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome: a systematic review and meta-analysis. PLoS One. 2014;9(9):e107466.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Singh V, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293–8.CrossRefPubMedGoogle Scholar
  117. 117.
    Eason JD, et al. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant. 2008;8(11):2243–51.CrossRefPubMedGoogle Scholar
  118. 118.
    Nazar A, et al. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol. 2013;58(1):51–7.CrossRefPubMedGoogle Scholar
  119. 119.
    Karagiannakis DS, et al. Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis. Hepatol Int. 2014;8(4):588–94.CrossRefPubMedGoogle Scholar
  120. 120.
    Ruiz-del-Arbol L, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine. Hepatology. 2013;58(5):1732–41.CrossRefPubMedGoogle Scholar
  121. 121.
    Cazzaniga M, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut. 2007;56(6):869–75.CrossRefPubMedPubMedCentralGoogle Scholar
  122. 122.
    Rabie RN, et al. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol. 2009;104(10):2458–66.CrossRefPubMedGoogle Scholar
  123. 123.
    Chen Y, et al. A detailed evaluation of cardiac function in cirrhotic patients and its alteration with or without liver transplantation. J Cardiol. 2016;67(2):140–6.CrossRefPubMedGoogle Scholar
  124. 124.
    Mohamed R, et al. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology. 1996;23(5):1128–34.CrossRefPubMedGoogle Scholar
  125. 125.
    Torregrosa M, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42(1):68–74.CrossRefPubMedGoogle Scholar
  126. 126.
    Tsochatzis EA, et al. Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther. 2010;31(3):366–74.CrossRefPubMedGoogle Scholar
  127. 127.
    Francoz C, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691–7.CrossRefPubMedPubMedCentralGoogle Scholar
  128. 128.
    Amitrano L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol. 2004;40(5):736–41.CrossRefPubMedGoogle Scholar
  129. 129.
    Amitrano L, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology. 2000;31(2):345–8.CrossRefPubMedGoogle Scholar
  130. 130.
    Nery F, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61(2):660–7.CrossRefPubMedGoogle Scholar
  131. 131.
    Zocco MA, et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol. 2009;51(4):682–9.CrossRefPubMedGoogle Scholar
  132. 132.
    American Cancer Society. Cancer facts and figures 2016. Atlanta, GA: American Cancer Society; 2016.Google Scholar
  133. 133.
    El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60(5):1767–75.CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    Ferlay J, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;​136(5):E359–86.CrossRefPubMedGoogle Scholar
  135. 135.
    N.A. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28(3):751–5.Google Scholar
  136. 136.
    Andersson KL, et al. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6(12):1418–24.CrossRefPubMedPubMedCentralGoogle Scholar
  137. 137.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.CrossRefPubMedPubMedCentralGoogle Scholar
  138. 138.
    Trojan J, Zangos S, Schnitzbauer AA. Diagnostics and treatment of hepatocellular carcinoma in 2016: standards and developments. Visc Med. 2016;32(2):116–20.CrossRefPubMedPubMedCentralGoogle Scholar
  139. 139.
    Adhoute X, et al. Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments. World J Hepatol. 2016;8(17):703–15.CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016;150(4):835–53.CrossRefPubMedGoogle Scholar
  141. 141.
    Bhardwaj N, Perera MT, Silva MA. Current treatment approaches to HCC with a special consideration to transplantation. J Transplant. 2016;2016:7926264.CrossRefPubMedPubMedCentralGoogle Scholar
  142. 142.
    Ripoll C, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481–8.CrossRefPubMedGoogle Scholar
  143. 143.
    Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg. 1964;1:1–85.PubMedGoogle Scholar
  144. 144.
    Cholongitas E, et al. Systematic review: the model for end-stage liver disease—should it replace Child-Pugh’s classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther. 2005;22(11–12):1079–89.CrossRefPubMedGoogle Scholar
  145. 145.
    Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59(3):1144–65.CrossRefPubMedGoogle Scholar
  146. 146.
    Malinchoc M, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71.CrossRefPubMedGoogle Scholar
  147. 147.
    Kamath PS, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.CrossRefPubMedGoogle Scholar
  148. 148.
    Wiesner RH, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001;7(7):567–80.CrossRefPubMedGoogle Scholar
  149. 149.
    Wiesner R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124(1):91–6.CrossRefPubMedGoogle Scholar
  150. 150.
    Hwang JH, et al. The role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc. 2014;80(2):221–7.CrossRefPubMedGoogle Scholar
  151. 151.
    Marcellin P, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–75.CrossRefPubMedGoogle Scholar
  152. 152.
    Xu B, et al. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30(2):372–8.CrossRefPubMedGoogle Scholar
  153. 153.
    Buti M, et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015;9(2):243–50.CrossRefPubMedPubMedCentralGoogle Scholar
  154. 154.
    D’Ambrosio R, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56(2):532–43.CrossRefPubMedGoogle Scholar
  155. 155.
    Hezode C, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther. 2011;34(6):656–63.CrossRefPubMedGoogle Scholar
  156. 156.
    Falize L, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology. 2006;44(2):472–7.CrossRefPubMedGoogle Scholar
  157. 157.
    Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol. 2004;40(4):646–52.CrossRefPubMedGoogle Scholar
  158. 158.
    Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med. 1997;126(9):682–8.CrossRefPubMedGoogle Scholar
  159. 159.
    Deniz K, et al. Regression of steatohepatitis-related cirrhosis. Semin Liver Dis. 2015;35(2):199–202.CrossRefPubMedGoogle Scholar
  160. 160.
    Yoon YJ, Friedman SL, Lee YA. Antifibrotic therapies: where are we now? Semin Liver Dis. 2016;36(1):87–98.CrossRefPubMedGoogle Scholar
  161. 161.
    Chang TT, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–93.CrossRefPubMedGoogle Scholar
  162. 162.
    Dixon LJ, et al. Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. Lab Invest. 2012;92(5):713–23.CrossRefPubMedPubMedCentralGoogle Scholar
  163. 163.
    Pockros PJ, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007;46(2):324–9.CrossRefPubMedGoogle Scholar
  164. 164.
    Baskin-Bey ES, et al. Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury. Am J Physiol Gastrointest Liver Physiol. 2005;288(2):G396–402.CrossRefPubMedGoogle Scholar
  165. 165.
    Abu-Elheiga L, et al. Acetyl-CoA carboxylase 2−/− mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions. J Biol Chem. 2012;287(15):12578–88.CrossRefPubMedPubMedCentralGoogle Scholar
  166. 166.
    Baeck C, et al. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology. 2014;59(3):1060–72.CrossRefPubMedGoogle Scholar
  167. 167.
    Sanyal AJ, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.CrossRefPubMedPubMedCentralGoogle Scholar
  168. 168.
    Kisseleva T, et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A. 2012;109(24):9448–53.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MedicineColumbia University Medical CenterNew YorkUSA
  2. 2.Transplant Initiative, Division of Digestive and Liver Diseases, Center for Liver Disease and TransplantationColumbia University Medical CenterNew YorkUSA

Personalised recommendations